Financials in USD. Standardized financial statements.
A compact view of how Pascal Biosciences Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue? | $670,157.26 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.02M | $8,336 | $16,338.14 | $12,382.03 | $13,338.32 |
| Gross Profit? | -$345,420.86 | -$8,336 | -$16,338.14 | -$12,382.03 | -$13,338.32 |
| Gross Margin? | -51.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $550,424.03 | $551,361.61 | $1.07M | $1.25M | $3.35M |
| Operating Income? | -$895,844.9 | -$559,698.68 | -$1.08M | -$1.26M | -$3.37M |
| EBITDA? | -$789,126.8 | -$497,511.29 | -$1.07M | -$1.25M | -$3.35M |
| Income Before Tax | -$398,945.11 | -$482,711.26 | -$1.09M | -$1.23M | -$3.41M |
| Income Tax Expense | $2.71 | -$1,417.14 | $0 | -$410.82 | -$17,871.04 |
| Net Income? | -$398,945.11 | -$482,711.26 | -$1.09M | -$1.23M | -$3.41M |
| EPS? | $-0.02 | $-0.04 | $-0.09 | $-0.11 | $-0.32 |
| Diluted EPS? | $-0.02 | $-0.04 | $-0.09 | $-0.11 | $-0.32 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality